Non Small Cell Lung Cancer: Clinical Trials

1,034 trials for Non Small Cell Lung Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

345 completed, 184 unknown, 173 recruiting, 132 terminated. 449 Phase 2, 274 Phase 1, 118 Not applicable, 71 Phase 3, 12 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2449Completed 133, Unknown 83, Recruiting 73, Terminated 60, Active not recruiting 48, Not yet recruiting 29, Withdrawn 18, Suspended 4, Enrolling by invitation 1
Phase 1274Completed 95, Recruiting 56, Terminated 54, Active not recruiting 31, Unknown 18, Withdrawn 10, Not yet recruiting 7, Suspended 2, Enrolling by invitation 1
Not applicable118Completed 38, Recruiting 21, Unknown 21, Terminated 16, Active not recruiting 9, Not yet recruiting 7, Withdrawn 6
Phase 371Completed 26, Unknown 14, Recruiting 10, Active not recruiting 7, Terminated 7, Not yet recruiting 5, Enrolling by invitation 1, Withdrawn 1
Early Phase 112Unknown 3, Not yet recruiting 2, Recruiting 2, Withdrawn 2, Completed 1, Suspended 1, Terminated 1
Phase 411Completed 5, Unknown 3, Recruiting 2, Terminated 1

Follow Non Small Cell Lung Cancer: new trials by email Literature Review of Non Small Cell Lung Cancer trials Research Report on Non Small Cell Lung Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)
Zanidatamab, Zongertinib - Non Small Cell Lung Cancer
Phase 1Not yet recruitingM.D. Anderson Cancer Center242027-04-012026-10-28
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz - Non Small Cell Lung Cancer, Cardiotoxicity
Phase 2RecruitingIndiana University102027-01-012026-11-10
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer
LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer
Phase 2Not yet recruitingCanadian Cancer Trials Group1602026-12-312026-10-27
The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer
SBRT in stage III NSCLC - Non Small Cell Lung Cancer
Not applicableNot yet recruitingAll India Institute of Medical Sciences202026-12-192026-09-24
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer
Phase 3Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.4362026-12-012026-10-26
3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial
3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping, 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping - Non Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingSt. Joseph's Healthcare Hamilton892026-12-012026-02-02
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG00313112 - Ovarian Cancer, Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingLG Chem2502026-12-012026-08-07
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)602026-11-222026-11-17
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
sample collection - Non Small Cell Lung Cancer, Melanoma (Skin Cancer)
Not applicableNot yet recruitingEuropean Institute of Oncology3602026-11-112026-11-04
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
TUB-040 - NSCLC, Non Small Cell Lung Cancer
Phase 2Not yet recruitingGilead Sciences802026-11-012026-09-16
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
SSGJ-706, SPGL008, Chemotherapy - Non Small Cell Lung Cancer
Phase 2Not yet recruitingShenyang Sunshine Pharmaceutical Co., LTD.2202026-11-012026-10-15
RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
Cemiplimab 350 mg IV - Non Small Cell Lung Cancer, Immunotherapy
Phase 2Not yet recruitingThe Netherlands Cancer Institute302026-11-012026-10-05
Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC
Zipalertinib - EGFR, Lung Cancer (NSCLC)
Phase 2Not yet recruitingStanford University422026-11-012026-09-03
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets
Ivonescimab, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer
Phase 2Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTC1582026-11-012026-06-04
ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in Patients Treated With Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer
Physical activity recommendations, Physical Activity (PA) Intervention - Lung Neoplasms, Non Small Cell Lung Cancer
Not applicableRecruitingCentre Leon Berard402026-10-292026-11-03
Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Not yet recruitingFox Chase Cancer Center2002026-10-062026-10-02
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
NovoTTF-200T System - NSCLC, Non Small Cell Lung Cancer
Not applicableWithdrawnUniversity of Texas Southwestern Medical Center2026-10-012026-10-23
SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC
Stereotactic Radiation Therapy, Envafolimab, Endostar - Non Small Cell Lung Cancer, Lung Neoplasms
Phase 2Not yet recruitingThe First People's Hospital of Lianyungang612026-10-012026-09-14
OPTIMISE Lung SABR
Five fraction Image-guided Stereotactic Ablative Radiotherapy (IG-SABR) treatment, Investigational three fraction image-guided Stereotactic Ablative Radiotherapy (IG-SABR) - Non Small Cell Lung Cancer
Phase 2RecruitingCancer Trials Ireland2082026-10-012026-10-16
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
Tislelizumab, Fecal Microbiota Transplant(FMT) - Non Small Cell Lung Cancer
Phase 2Not yet recruitingSe-Hoon Lee152026-09-302026-08-11

Showing 20 of 1034. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (1034)  ·  Lung Neoplasms (164)  ·  Melanoma (77)  ·  Neoplasms (69)  ·  Colorectal Neoplasms (65)  ·  Ovarian Neoplasms (49)  ·  Pancreatic Neoplasms (49)  ·  Breast Neoplasms (48)  ·  Squamous Cell Carcinoma of Head and Neck (48)  ·  Neoplasm Metastasis (47)  ·  Triple Negative Breast Neoplasms (43)  ·  Carcinoma, Renal Cell (42)  ·  Small Cell Lung Carcinoma (39)  ·  Stomach Neoplasms (34)  ·  Uterine Cervical Neoplasms (32)

Broader conditions

Neoplasms by Site (1033)  ·  Respiratory Tract Diseases (1033)  ·  Bronchial Neoplasms (1032)  ·  Carcinoma, Bronchogenic (1031)  ·  Lung Diseases (1031)  ·  Respiratory Tract Neoplasms (1031)  ·  Thoracic Neoplasms (1031)  ·  Neoplasms (965)  ·  Lung Neoplasms (870)  ·  Neoplasms by Histologic Type (166)  ·  Skin Diseases (137)  ·  Skin and Connective Tissue Diseases (137)  ·  Neoplasms, Glandular and Epithelial (132)  ·  Digestive System Diseases (117)  ·  Digestive System Neoplasms (115)

Interventions

Pemetrexed (101)  ·  Carboplatin (92)  ·  pembrolizumab (77)  ·  Cisplatin (63)  ·  Docetaxel (55)  ·  Paclitaxel (50)  ·  Nivolumab (44)  ·  Gemcitabine (36)  ·  Drug Therapy (30)  ·  Erlotinib Hydrochloride (28)  ·  osimertinib (28)  ·  Bevacizumab (27)  ·  Radiosurgery (24)  ·  atezolizumab (22)  ·  Ipilimumab (20)

Sponsors

Eli Lilly and Company (27)  ·  AstraZeneca (23)  ·  Hunan Province Tumor Hospital (16)  ·  Hellenic Oncology Research Group (13)  ·  Memorial Sloan Kettering Cancer Center (13)  ·  Sun Yat-sen University (13)  ·  Tianjin Medical University Cancer Institute and Hospital (12)  ·  Duke University (9)  ·  National University Hospital, Singapore (8)  ·  Shanghai Pulmonary Hospital, Shanghai, China (8)  ·  University Health Network, Toronto (8)  ·  Yonsei University (8)  ·  Fundación GECP (7)  ·  Intergroupe Francophone de Cancerologie Thoracique (7)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (7)

Countries

United States (378)  ·  China (226)  ·  France (119)  ·  Spain (94)  ·  Italy (83)  ·  Canada (73)  ·  South Korea (73)  ·  Australia (52)  ·  United Kingdom (51)  ·  Germany (45)  ·  Netherlands (44)  ·  Taiwan (44)  ·  Belgium (43)  ·  Greece (33)  ·  Poland (25)

Top investigators

Mariano Provencio, MD (7)  ·  Vassilis Georgoulias, MD (7)  ·  Yongchang Zhang, MD (5)  ·  Armando Santoro, MD (3)  ·  Daniel Morgensztern, M.D. (3)  ·  Dirk De Ruysscher, MD, PhD (3)  ·  Francesco Grossi, MD (3)

Results publications

PMID 23578144, PMID 25175099, PMID 25881079, PMID 26291023, PMID 30171779, PMID 33166722, PMID 35048355, PMID 36053283, PMID 40179330, PMID 42279342, PMID 11180735, PMID 11282431, PMID 11452123, PMID 11597807, PMID 11740992, PMID 12237924, PMID 12683544, PMID 12738306, PMID 12738307, PMID 12750523, PMID 12826306, PMID 1324899, PMID 14596509, PMID 14605072, PMID 15302749, PMID 15378503, PMID 15383520, PMID 15949587, PMID 16115740, PMID 16169670, PMID 16236914, PMID 16391372, PMID 16757720, PMID 16765528, PMID 17167516, PMID 17229875, PMID 17488518, PMID 17925563, PMID 18305939, PMID 18565793, PMID 18581114, PMID 18683299, PMID 18725106, PMID 19251380, PMID 19403881, PMID 19427740, PMID 19556022, PMID 19801201, PMID 20233825, PMID 20923544

NIH funding

2018 (8), 2023 (7), 2014 (6), 2017 (6), 2009 (5), 2016 (4), 2015 (3), 2019 (3), 2025 (3), P30CA012197 (3), 2004 (2), 2005 (1), 2008 (1), R01CA211705 (1), R01CA258681 (1)